Pharma VC Funds

Loup Ventures is a Minneapolis and New York-based venture capital firm focused on frontier technologies, including artificial intelligence (AI), augmented reality (AR), virtual reality (VR), and robotics. Founded in 2017 by Andrew Murphy, Doug Clinton, and Gene Munster, the firm invests primarily in early-stage companies that are at the intersection of these emerging technologies. Loup Ventures is research-driven, leveraging in-depth analysis and insights to guide its investment decisions. Notable investments include Neurable, an AI company advancing brain-computer interfaces, and Skupos, a platform providing data solutions for convenience stores. The firm is known for its focus on high-impact sectors like neurotechnology, and the future of transportation, with its portfolio companies aiming to shape the way humans interact with machines and the digital world. Geographically, Loup Ventures focuses on investments across the U.S., with its team frequently engaging in thought leadership through articles and podcasts on technological trends. Their investment strategy emphasizes deep involvement, supporting founders not only financially but also with insights derived from their rigorous market research. The team, led by Gene Munster, a well-known tech analyst, and Andrew Murphy, brings extensive experience in tech and finance. Loup Ventures prefers a hands-on approach, often leading rounds and staying actively involved in guiding startups to scale. Startups looking to attract their attention should highlight disruptive tech in AI or AR, showcasing robust market research and a clear vision for the future.

Lowercarbon Capital, founded in 2018 by Chris and Crystal Sacca, is a venture capital firm dedicated to combating climate change through investments in innovative technologies. Based in Jackson, Wyoming, the firm focuses on backing companies that reduce CO2 emissions, remove existing carbon from the atmosphere, and develop solutions to mitigate the impacts of climate change. Notable investments include Lilac Solutions, which is revolutionizing lithium extraction; Solugen, which produces chemicals using enzymes instead of oil; Commonwealth Fusion Systems, working on fusion energy; and Mosa Meat, creating lab-grown meat to reduce livestock emissions. Lowercarbon Capital has invested in over 160 companies, aiming to combine hard science with ambitious goals to tackle climate challenges. The firm’s strategy emphasizes both financial returns and environmental impact, supporting startups from the R&D stage to seed funding with checks ranging from $50,000 to $1 million. Their comprehensive approach includes not only capital but also strategic guidance and support for founders through a robust ecosystem of industry experts and fellow entrepreneurs​. Led by a team of experienced investors and scientists, including managing partner Chris Sacca, Lowercarbon Capital is positioned at the forefront of climate tech innovation, making significant strides in various sectors such as energy, agriculture, and industrial materials.

Lowercase Capital, founded by Chris Sacca in 2010, is a renowned venture capital firm based in San Francisco. The firm specializes in early-stage investments and has built a notable portfolio featuring some of the most successful tech startups of the past decade. Their investments include iconic companies such as Twitter, Uber, Instagram, Twilio, Stripe, and Kickstarter. These high-profile successes have helped establish Lowercase Capital as a significant player in the venture capital landscape. Lowercase Capital has made around 250 investments, spanning various industries including technology, media, and consumer products. They are particularly known for their involvement in Y Combinator companies, investing in startups like 9gag, Stripe, and Docker. The firm's strategy involves not only providing capital but also offering extensive support and guidance to their portfolio companies, leveraging Chris Sacca's extensive experience and network within the tech industry. The firm's notable exits include Slack, Instagram, and Twitter, which have contributed significantly to Lowercase Capital's reputation and financial success. These exits highlight the firm's ability to identify and nurture companies with substantial growth potential. Lowercase Capital is also known for its philanthropic efforts, supporting startups that empower and help people in need, such as charity: water and the Anti-Recidivism Coalition. Chris Sacca, the founder, has been recognized for his impactful contributions to both the business and philanthropic sectors, making him a prominent figure in the venture capital community.

Loyal VC is a global venture fund established in 2018 that operates a startup index fund with over 350 investments across more than 60 countries. The firm is known for its unique gate-stage investment process, which reduces systemic bias and aims to unlock greater returns. This process involves multiple rounds of diligence and quarterly redemptions, offering flexibility to high-net-worth individuals and institutions. Loyal VC collaborates closely with INSEAD, Founder Institute, and a network of over 1,000 advisors. This extensive network supports a diverse portfolio of founders, with more than 30% of the portfolio companies led by women CEOs and nearly 30% based in emerging markets. The firm places a strong emphasis on social impact, with 80% of its investments aligned with one or more of the UN Sustainable Development Goals (SDGs). Notable investments by Loyal VC include Sama, a company that brings transparency and verifiability to cross-border blue-collar recruitment, and TechStyle, a digital marketplace for sustainable material sourcing in the fashion industry. The firm also supports companies like CurieMD, a telemedicine platform for menopause care, and Milestone, a financial literacy app aimed at helping parents raise financially responsible children. Loyal VC’s investment focus spans various sectors, including cleantech, fintech, healthcare, and more, reflecting their commitment to backing innovative solutions across the globe. For more information, you can visit their official website.

Ludlow Ventures, founded in 2009 and based in Detroit, Michigan, is a venture capital firm that takes a unique approach to investing by emphasizing strong personal relationships with entrepreneurs. The firm focuses on early-stage investments, particularly in the technology sector. Ludlow Ventures has built a robust portfolio, with notable companies such as Honey, a browser extension for online shopping deals acquired by PayPal; Wag, a dog-walking service; and Product Hunt, a platform for discovering new products. The firm has made over 160 investments and has achieved 24 exits, showcasing their ability to identify and support high-potential startups. Other significant investments include Headout, an on-demand mobile platform for booking tours and activities, and CoverTree, an insurtech company focused on property insurance. Ludlow Ventures operates with a philosophy of "VC without ego," striving to be collaborative and supportive partners to their portfolio companies. The team, led by Managing Partner Jonathon Triest, prides itself on being deeply involved in the success of the startups they back, providing not just capital but also strategic advice and resources.

Lumira Ventures is a prominent venture capital firm specializing in life sciences and healthcare investments. Established in 1989 and headquartered in Toronto, Canada, Lumira Ventures has a robust presence across North America, with offices in Toronto, Montreal, Vancouver, and Boston. The firm focuses on backing innovative biotechnology and medical technology companies that have the potential to address significant unmet medical needs and improve healthcare quality globally. The firm's investment portfolio includes a wide range of companies such as Depomed, Guava Technologies, Think Research, and U-Systems, showcasing their diverse interest in biopharmaceuticals and medical devices. Notable recent investments include Antiva Biosciences, developing topical therapies for HPV-related pre-cancerous lesions, and Arclight Therapeutics, focusing on neurodegenerative diseases. Lumira Ventures' investment strategy involves providing substantial support to their portfolio companies, from early-stage funding to strategic guidance. They recently closed their Lumira Ventures IV fund at $220 million, the largest life sciences venture fund ever raised in Canada, highlighting their significant role in the sector. Overall, Lumira Ventures is dedicated to advancing healthcare innovation through strategic investments and active support of pioneering companies in the life sciences domain.

LUMO Labs is a dynamic venture capital firm based in Eindhoven, Netherlands, that prioritizes impact-driven investments in emerging digital technologies. Focused on pre-seed to Series A stages, LUMO Labs targets startups in fields like AI, blockchain, robotics, IoT, and AR/VR. The firm is deeply committed to supporting innovations that address global challenges related to sustainable cities, health, well-being, and education. Its portfolio includes companies such as Alphabeats, Enliven, and Roboat, all of which push the boundaries of technology while contributing to societal progress. Founded by Andy Lürling and Sven Bakkes, LUMO Labs has gained recognition for its hands-on approach. Startups in their portfolio benefit from a two-year venture builder program, which provides personalized coaching, access to expert networks, and support tailored to each company's unique needs. This program focuses on four key pillars: leadership, product-market fit, storytelling, and follow-on investment, ensuring that startups scale effectively both economically and socially. With the recent launch of the €100 million LUMO Rise Fund, LUMO Labs has expanded its scope across Europe, investing in climate action, digital security, and projects aligned with the UN’s Sustainable Development Goals. LUMO Labs is driven by the belief that technological advancements can serve as powerful tools for creating a better and more sustainable future.

Lux Capital is a leading venture capital firm renowned for its investments in groundbreaking science and technology ventures. With a portfolio boasting companies like Recursion Pharmaceuticals, Desktop Metal, and Matterport, Lux Capital focuses on industries such as biotechnology, material science, and artificial intelligence. The firm invests primarily in early-stage startups but is versatile enough to support companies through later stages as well. Lux Capital is geographically centered in the United States, with a strong presence in New York and Silicon Valley. Their investment strategy is defined by backing counter-conventional ideas that push the boundaries of current technology and science. They are known for making substantial investments, often leading funding rounds, and providing robust support to their portfolio companies to ensure their long-term success. The firm is managed by an experienced team including co-founders Peter Hébert, Robert Paull, and Joshua Wolfe. Their approach is hands-on, offering not just capital but also strategic guidance, networking opportunities, and operational support. Lux Capital values innovative pitches and prefers to be approached with well-researched and transformative ideas. In recent years, Lux Capital has been highly active, raising significant funds like the $1.15 billion for its eighth fund. The firm’s commitment to pioneering technologies is evident in their diverse investments, from AI-driven biotech firms like Evolutionary Scale to innovative aerospace companies like Planet.

M Ventures is the strategic corporate venture capital fund of Merck KGaA (Darmstadt, Germany), created in 2009 and headquartered in Amsterdam, Netherlands, with additional offices in Germany, Israel, and the United States. The fund invests with dual strategic and financial objectives across biotechnology and technology, covering four areas: healthcare drug development, life science tools, electronics, and frontier technology and sustainability. In 2021, Merck expanded M Ventures with an additional €600 million commitment — the third increase since the fund's creation — enabling larger and more frequent investments. The team of seven is led by CEO Howard H. Thaw. M Ventures leads rounds and has made 133 investments with 20 portfolio exits, the most recent being Calypso Biotech in January 2024. A recent landmark deal was the co-led $75.5 million oversubscribed Series A for Actithera in July 2025, a radiopharmaceutical biotech developing next-generation radioligand therapies. The biotech portfolio focuses on emerging biotechnologies leading to differentiated drugs, R&D tools, and platforms with significant potential to improve patient outcomes. The technology portfolio invests in companies developing new solutions for information access, storage, processing, and display, as well as sustainability challenges. Geographic scope is global, with concentrations in Europe, Israel, and the United States. M Ventures takes an active role in portfolio companies and facilitates seed-stage company creation, early-stage syndicated investments, and the creation and funding of Merck spin-offs. Portfolio companies benefit from Merck's deep scientific networks, laboratory infrastructure, and relationships with global pharmaceutical and specialty chemical companies across Merck's three business sectors: life science, healthcare, and electronics.

M12, Microsoft's venture fund, focuses on early-stage investments, primarily in Series A and B rounds. Established in 2016, M12 has quickly become a significant player in the venture capital landscape, leveraging Microsoft's extensive network and resources to support its portfolio companies. M12's investment areas include AI, cloud infrastructure, cybersecurity, developer tools, vertical SaaS, and emerging technologies like Web3 and gaming. Notable investments by M12 include companies such as SpaceX, Addepar, GoPuff, BitGo, and Dataminr. Additionally, M12 has backed promising startups like BlueVine in vertical SaaS, Bolster in cybersecurity, and Bonsai in AI. M12 also focuses on fostering innovative solutions in autonomous systems and frontier technologies​. The fund operates with a close alignment to Microsoft, which allows it to provide unique benefits and opportunities for its portfolio companies, such as integrations with Microsoft Azure and other enterprise solutions. This strategic alignment helps startups accelerate their growth and expand their market reach by leveraging Microsoft's extensive ecosystem.

M13 is a venture capital firm based in Santa Monica, California, known for its early-stage investments in disruptive technology and consumer-focused companies. Founded in 2016 by brothers Carter and Courtney Reum, M13 has established a robust portfolio that includes notable companies such as Ring, Cue, Daily Harvest, FabFitFun, ClassPass, Matterport, and Capsule. M13's investment strategy spans several sectors including health, commerce, work, and money, with a strong focus on infrastructure technologies such as AI and web3. The firm leverages its Propulsion Platform, which combines operational expertise and strategic guidance to help startups scale efficiently. This platform ensures that each founder receives tailored support, significantly enhancing their chances of success. M13 has recently launched its third fund, raising $400 million to continue backing early-stage teams. Their approach involves writing checks of up to $15 million from Seed to Series B stages, often leading the investment rounds. This fund aims to capitalize on the evolving consumer behavior and the growing importance of horizontal technology layers, including blockchain-based applications governed through tokens.

M25 is an early-stage venture capital firm based in Chicago, focusing on investments in startups headquartered in the Midwest. Founded in 2015, M25 has quickly become one of the most active seed investors in the region, with over 90 investments across a variety of industries, including AI, fintech, e-commerce, healthcare, and software. Notable investments from M25 include companies like Upsie, a warranty services provider; Avail, a platform for landlords and tenants; and PactSafe, a contract acceptance platform. The firm has a strong focus on supporting innovative and high-growth potential startups, leveraging their extensive network and resources to help these companies scale effectively. M25’s investment strategy involves making initial investments ranging from $500,000 to $1.5 million and often taking board seats to provide strategic guidance. The firm emphasizes a data-driven approach to investment decisions and maintains a hands-on relationship with its portfolio companies to support their growth and success.

MaC Venture Capital, co-founded by Adrian Fenty, Marlon Nichols, Michael Palank, and Charles D. King, is a prominent seed-stage venture capital firm headquartered in Los Angeles and Silicon Valley. The fund focuses on investing in technology startups that leverage cultural shifts and trends. Notable investments include Gimlet Media, Truebill, Pipe, Edge Delta, Stoke, Zigazoo, and Spartan Radar, reflecting their strategic emphasis on technology, fintech, media, and mobile sectors. MaC VC is distinguished by its commitment to diversity; 36% of their portfolio companies are led by women, and 69% by BIPOC founders. Their investment strategy centers on backing early-stage companies with innovative solutions addressing large market needs. They typically lead rounds and write initial checks of significant amounts, maintaining substantial reserves to support follow-on investments in high-performing portfolio companies. The firm’s team, which includes key figures like Adrian Fenty and Marlon Nichols, brings a wealth of expertise across technology, politics, entertainment, and finance. This diverse leadership enhances their ability to provide comprehensive support in operations, brand building, and strategic introductions, crucial for scaling startups.\

Magnetic Ventures is a Miami Beach-based venture capital firm founded in 2018 by Christine Aylward. The firm specializes in early-stage investments, primarily focusing on companies at the intersection of technology and life sciences. With a strong emphasis on AI, machine learning, and biotech, Magnetic Ventures backs founders who are developing transformative solutions in healthcare. Their investment portfolio includes cutting-edge companies like Deep Genomics, Spotlight Therapeutics, and Paradigm, which are revolutionizing areas like drug discovery, gene editing, and clinical research. Magnetic Ventures typically makes initial investments ranging from $1 million to $6 million, entering at seed or Series A stages. The firm is deeply involved in supporting its portfolio companies throughout their growth, leveraging its extensive experience in healthcare regulation and commercialization. Their geographical focus is North America and Europe, with offices in Miami, Boston, and Research Triangle Park​. This hands-on approach and a mission to advance patient care through technology have made Magnetic Ventures a key player in driving innovation across the healthcare landscape.

Main Sequence Ventures, founded in 2017 and backed by Australia's national science agency CSIRO, is a venture capital firm that focuses on deep tech and frontier technologies. The firm is headquartered in Australia and aims to solve significant global challenges through its investments. Main Sequence has a unique "venture science" model, which starts by identifying big challenges and bringing together science, people, and investment to create and fund companies that can address these issues. Main Sequence Ventures has built a strong portfolio with notable companies such as Q-CTRL, which makes quantum technology useful; Gilmour Space, which focuses on efficient satellite launches; and Emesent, a leader in robotics and autonomy technology. Other significant investments include Myriota, which provides low-cost satellite connectivity, and V2food, which develops sustainable meat alternatives. The firm's second fund, which raised $250 million, focuses on areas such as decarbonization, healthcare, and space technology. This fund supports companies like Kasada, a cybersecurity firm stopping bot attacks, and RapidAIM, which offers biosecurity solutions for pest management. Main Sequence Ventures is dedicated to leveraging scientific discoveries to create impactful, high-growth companies that can address some of the world's most pressing challenges. Their strategic investment approach and strong support for portfolio companies highlight their commitment to driving innovation and technological advancement globally.

Majycc Capital is a prominent French venture capital firm that focuses on revolutionizing the healthcare sector through strategic investments in innovative startups. Established in 2022 through the merger of Majycc eSanté Invest and UI Investissement, the firm now manages over €700 million, primarily dedicated to eHealth, MedTech, and BioTech ventures. Majycc Capital is particularly active in the Series A and B funding stages, where it seeks out high-potential startups across France and Europe that are positioned to deliver transformative advancements in healthcare. The firm's investment strategy goes beyond financial support. Leveraging its deep connections within the healthcare ecosystem, Majycc Capital provides comprehensive strategic assistance to its portfolio companies. This includes guidance on navigating complex regulatory pathways, insights into market dynamics, and support in business development—key elements that are crucial for scaling healthcare innovations. Majycc’s extensive network within the healthcare industry, including partnerships with healthcare manufacturers and private clinic groups, further amplifies the growth potential of the startups it backs. Majycc Capital’s commitment to innovation is underscored by its regional presence, with 13 offices throughout France, ensuring that it remains closely involved with local economies and emerging companies. The firm’s dedicated team, led by experienced professionals, is deeply invested in the success of its portfolio companies, working tirelessly to ensure they achieve their full potential in the competitive healthcare market​.

Maki.vc is a seed-stage venture capital firm that partners with deep tech and brand-driven startups focused on challenging category norms. Founded in 2018, Maki.vc invests in early-stage companies from their inception to Series A, emphasizing scientific advancements and unique customer understanding. Maki.vc has a global mandate, with a strong presence in the Nordics. The firm’s portfolio includes companies across various sectors such as AI, quantum computing, and sustainability. Notable investments include IQM, a leader in quantum computing; Spinnova, which develops sustainable textiles; and Onego Bio, which creates animal-free egg protein using novel technology. The firm’s approach goes beyond providing capital. Maki.vc supports its portfolio companies through Maki House, a platform that offers strategic guidance and a network of experts to help startups scale and achieve long-term success. Their investment philosophy centers on future-proofing companies by integrating ESG principles into their operations from the start, ensuring sustainability and long-term profitability.

Mandi Ventures is an early-stage venture capital fund based in São Paulo, Brazil, with additional offices in Brussels. The fund focuses on investing in disruptive technologies within the food, agriculture, and climate tech sectors. Mandi Ventures primarily targets startups involved in novel foods, biotech, life sciences, robotics, and precision farming, aiming to reshape how we produce and consume food. Their global investment reach includes startups across the Americas, Europe, and Israel. Mandi Ventures supports seed-stage companies, offering not just capital but also strategic business expertise to help startups commercialize their innovations. They focus on areas like supply chain logistics, wellness, sustainability, and SaaS platforms within the food and agriculture ecosystem. Notable investments include companies driving innovation in biotech and precision farming, ensuring that the fund stays at the forefront of transformative food technologies. With a strong network and industry connections, Mandi Ventures plays an active role in guiding its portfolio companies through their growth stages, from scaling operations to market expansion.

Mangrove Capital Partners is a dynamic venture capital firm known for its bold, patient approach and commitment to supporting innovative entrepreneurs globally. The firm, headquartered in Luxembourg, has a strong presence in Europe with offices in Berlin, Paris, Barcelona, and London, as well as in Tel Aviv, Israel. Mangrove has a proven track record of backing successful companies, having been early investors in five unicorns: Skype, Wix, WalkMe, K Health, and TBOL. Mangrove's investment strategy focuses on early-stage tech startups, often partnering with entrepreneurs even before their product launch. They are particularly interested in transformational ideas across various sectors, including fintech, e-commerce, and health tech. Some of their rising stars include Red Points, Adverity, and Flo Health. The firm is known for its hands-on support, offering not just capital but also strategic guidance and operational assistance. Mangrove's team, comprising experienced entrepreneurs and operators, works closely with startups to navigate the challenges of scaling and growth. This approach is reinforced by their reputation for being more than just investors—they are seen as anchor partners deeply involved in their portfolio companies' success.

Manta Ray Ventures is an early-stage venture capital firm based in London, founded by Sebastian Kulczyk. The firm focuses on backing mission-driven founders who aim to address significant global challenges using advanced technologies. Manta Ray Ventures provides flexible and patient capital, leveraging their resources and networks to support their portfolio companies. Their diverse portfolio includes notable investments such as Volocopter, a manufacturer of electric copters for urban mobility; Astranis, a developer of satellite-based communication services; and Bluu Biosciences, focused on food and agriculture technology. They also have investments in companies like Epic Games, the creator of the popular game Fortnite, and Juvena Therapeutics, which is involved in drug discovery and clinical trials. Manta Ray Ventures has achieved significant exits, including the acquisition of Frontier Car Group by OLX Group and the merger of Forge Platform. The firm has also seen one of its portfolio companies, Bridge, go public on the Tokyo Stock Exchange. Led by a team of experienced professionals, including Managing Partner Lawrence Barclay and Partner Leah von Siemens, Manta Ray Ventures is dedicated to fostering innovation and supporting the growth of transformative technologies across various industries.

March Capital, established in 2014 and based in Santa Monica, California, is a venture growth firm focused on next-generation technology companies. The firm emphasizes sectors such as enterprise AI, fintech, and commerce enablement, aiming to partner with visionary entrepreneurs and support their growth to market leadership. Notable investments in March Capital's portfolio include CrowdStrike, a leader in cybersecurity; BillDesk, India's premier payments network; and Canva, an online design platform. They have also invested in companies like ActionIQ, a customer data platform, and ASAPP, an AI software company automating customer service. March Capital has seen successful exits from companies such as CarTrade, an online automotive marketplace, and Forescout, a cybersecurity firm. The firm is known for its collaborative approach, working closely with portfolio companies to provide strategic guidance and leveraging their extensive network to drive growth and success. They focus on building concentrated portfolios and doubling down on high-potential investments, ensuring significant impact and returns. March Capital also hosts The Montgomery Summit, a premier technology conference that gathers leading entrepreneurs, investors, and corporate executives to foster relationships and catalyze growth for portfolio companies.

MarsBio is a Los Angeles-based venture capital fund that focuses on investing in pre-seed and seed-stage biotech startups. The firm specializes in biosciences and frontier technologies, targeting innovations in healthcare, therapeutics, synthetic biology, and the future of food. With check sizes ranging from $250K to $500K, MarsBio supports startups that push the boundaries of biology, using it as a tool for manufacturing and sustainable solutions. Their portfolio reflects an interest in companies working on immunology, oncology, neuroscience, and bio-enabling technologies, such as research tools and bioelectronics. Co-founded by Rob Rhinehart, best known for creating Soylent, MarsBio aims to back visionary founders with disruptive ideas. The firm emphasizes its support for entrepreneurs tackling complex problems, particularly those related to sustainable food supply chains and novel healthcare solutions. MarsBio’s strategy is to engage deeply with founders at the earliest stages, helping them scale innovative solutions that have the potential to redefine industries. MarsBio primarily invests in U.S.-based companies and leverages its expertise and network to drive transformational progress in biosciences. They’re especially drawn to startups that are pioneering new technologies that could shape the next era of healthcare and sustainable living.

Martlet Capital is an early-stage venture capital firm based in Cambridge, UK, focused on deep technology and life sciences B2B startups. Since its inception in 2011, Martlet Capital has invested in over 70 companies, providing patient capital to high-growth potential ventures. Their portfolio spans sectors like artificial intelligence, digital health, personalized medicine, engineering, IoT, new materials, and quantum technologies. Notable investments include Echion Technologies, known for their superfast-charging lithium-ion batteries, and IESO Digital Health, which provides real-time cognitive behavioral therapy online. They have also invested in companies like Converge, developing wireless sensor networks for real-time construction monitoring, and Dogtooth Technologies, which creates autonomous robots for productivity enhancement. Martlet Capital typically leads funding rounds and supports its portfolio companies beyond capital with strategic guidance, network access, and operational expertise. Their successful exits include Arachnys, Audio Analytic, and Cambridge CMOS Sensors. Martlet Capital's team comprises experienced investors and entrepreneurs, who actively engage in nurturing startups from early commercialization stages to scaling. Their investment strategy focuses on fostering innovation and driving growth in the UK, particularly within the Cambridge tech ecosystem. For startups seeking investment, Martlet Capital looks for innovative solutions with scalable business models in deep tech and life sciences. They prioritize strong leadership teams and groundbreaking technologies that can make a significant impact on their respective industries.

MassMutual Ventures (MMV) is a global venture capital firm that invests in a range of sectors, including enterprise software, cybersecurity, financial technology, digital health, and climate technology. Founded in 2014 and based in Boston, MMV also has offices in London and Singapore. The firm manages over $1 billion in investment capital and focuses on accelerating the growth of its portfolio companies by providing capital, connections, and strategic advice. Notable investments by MMV include Prove, a leader in digital identity solutions; Daye, a gynecological health startup; and Griffin, a developer-friendly Banking as a Service platform. The firm's portfolio spans across various stages of investment, from seed to growth stage, with typical check sizes ranging from $100,000 to $5 million. In 2022, MMV launched a $100 million Climate Technology Fund to invest in early and growth-stage companies addressing climate change. This fund aims to support 15 to 20 companies developing solutions to mitigate, measure, and manage climate change impacts, further expanding MMV's commitment to sustainable innovation​. The team at MMV includes experienced investors, former entrepreneurs, and operators, such as Doug Russell, the Managing Partner and Head of MMV, and Ryan Collins, the Managing Partner for Europe and APAC. Their deep industry expertise and extensive network help portfolio companies scale and succeed in competitive markets.

MassVentures, established in 1978 as the Massachusetts Technology Development Corporation, is a venture capital firm dedicated to supporting early-stage technology startups in Massachusetts. With a mission to bridge the capital gap for startups, MassVentures has invested $91.9 million in 152 companies from its inception through June 2019. The firm focuses on diverse sectors including life sciences, robotics, and advanced manufacturing, and typically makes initial investments of $250,000 to $500,000. Notable investments include Battery Resourcers, Inkbit, and Pison. Additionally, MassVentures administers the Small Business Innovation Research Targeted Technologies (SBIR-TT) grant program, which has awarded $22.1 million to 79 companies since 2012. This program supports the commercialization of innovations emerging from academic research and small businesses, fostering technological advancement and job creation in the state. MassVentures is led by an 11-member board of directors, predominantly from the private sector, and operates with a small team based in Boston. The firm not only provides financial support but also strategic guidance and operational expertise to help startups scale successfully. Through its investments and grant programs, MassVentures plays a crucial role in the growth of Massachusetts' innovation ecosystem, aiming to enhance the state's economic development by nurturing high-potential startups.

Material Impact, founded in 2015 by Adam Sharkawy and Carmichael Roberts, is a venture capital firm based in Boston, Massachusetts, that focuses on transforming material science innovations into impactful real-world applications. The firm is dedicated to addressing large-scale problems related to food, water, sustainable manufacturing, transportation, mobility, and healthcare through its investments in deep tech companies. Material Impact's portfolio includes notable companies such as DetraPel, Bloomer Tech, Folio Photonics, and Nohbo. These investments span a range of industries, including specialty chemicals, healthcare monitoring equipment, IT storage, and personal products. The firm’s hands-on approach to building companies involves working closely with founders to guide them through critical growth stages​. In 2023, Material Impact announced its $352 million Fund III, aimed at continuing its mission to support early-stage startups that leverage material science to solve pressing global challenges. This new fund allows Material Impact to take larger ownership stakes while maintaining its active role in company development. The firm's commitment to diversity and impact is reflected in its alignment with the United Nations Sustainable Development Goals and its diverse leadership team​. For entrepreneurs interested in partnering with Material Impact, the firm values innovations that have strong scientific foundations and the potential to address significant human needs. Material Impact provides not only capital but also strategic and operational support, often embedding its team members within portfolio companies to ensure their success.

Matrix Partners is a powerhouse in early-stage venture capital, boasting over four decades of experience and $4 billion in assets under management. Their portfolio spans transformative startups like Canva, Afterpay, Oculus, and Hubspot, among 65+ IPOs and 110+ acquisitions. With offices in San Francisco and Boston, Matrix invests globally, focusing on the U.S., India, and China. Their sweet spot is in sectors like AI, fintech, digital health, and B2B SaaS. Matrix is known for its commitment to backing founders from seed through Series A, providing checks ranging from $100K to $1M. They emphasize patience, nurturing relationships with company builders and former founders, helping them scale effectively. While they often lead rounds, Matrix also co-invests, partnering with top VCs like Y Combinator and Andreessen Horowitz. Key team members include Pranay Desai and Paul Sherer in San Francisco, and they maintain a reputation for being hands-on, leveraging deep expertise across diverse tech-driven industries. Entrepreneurs seeking funding should approach Matrix with a clear vision for scalable innovation, as the firm is laser-focused on high-impact, technology-driven ventures.

Matterwave Ventures, established in early 2022 from the former btov Industrial Technologies team, focuses on investing in early-stage European industrial hardware and software companies. Headquartered in Munich, Germany, Matterwave aims to empower startups to become global leaders in the industrial sector. Their €130M Matterwave Industrial Technologies II fund backs 20-25 companies, with initial investments ranging from €1M-4M and up to €10M in follow-on rounds. Matterwave's investment strategy prioritizes automation, digitalization, and resource efficiency within industrial value chains. They target technologies in enterprise automation, frontier tech, production optimization, and sensor-powered solutions. Notable portfolio companies include TVARIT, which specializes in AI for sustainable manufacturing, and Orcan Energy, focusing on industrial heat capture. Led by a team with over 50 years of combined venture capital experience, Matterwave Ventures leverages deep industry knowledge and strong market connections to support its portfolio companies. The team includes experts with backgrounds in engineering, physics, and technology commercialization, ensuring they provide comprehensive strategic guidance. Matterwave Ventures emphasizes sustainability and resource efficiency, aligning their investments with the EU's Sustainable Finance Disclosure Regulation. This commitment reflects their broader goal of enhancing Europe's industrial competitiveness while addressing environmental challenges​.

Maven Ventures is a seed-stage venture capital firm specializing in consumer software startups. With a notable track record, Maven has backed major successes like Zoom, Cruise, and Epic!, achieving significant exits and IPOs. Founded in 2013, the firm has maintained a focused strategy, supporting around 50 high-potential startups with investments typically ranging from $750K to $1M. The firm is keenly interested in emerging consumer trends and technologies, investing in sectors like digital health, autonomous vehicles, fintech, and AI-driven solutions. Geographic focus primarily includes the United States, particularly Silicon Valley, but Maven also invests in global opportunities. Maven Ventures' strategy is highly selective, with a small team providing hands-on support to a concentrated portfolio. The team, led by seasoned investors like Jim Scheinman, focuses on building deep relationships with founders, offering critical guidance on marketing, product development, and go-to-market strategies. Recent investments include startups like Hello Heart, which provides mobile solutions for heart health, and Wildtype, a company pioneering lab-grown seafood. The firm has a proactive approach to diversity, supporting a range of women-led and minority-led startups. Maven Ventures prefers to be approached through a well-articulated pitch that demonstrates a strong market need and scalable solution. With a reputation for nurturing bold founders and transformative ideas, Maven Ventures remains a prominent player in the VC landscape, consistently driving innovation and impactful growth in the consumer tech sector​.

Maveron, a consumer-only venture capital firm, was founded in 1998 by Dan Levitan and Howard Schultz, the visionary behind Starbucks. The firm focuses on early-stage investments in transformative consumer brands. With a keen understanding of consumer behavior and market trends, Maveron has built a diverse portfolio that includes notable companies like Allbirds, Everlane, and Zulily. Maveron operates with a mission to back entrepreneurs who aim to change how people live, work, learn, play, eat, and stay well. Their investments span various consumer sectors such as health and wellness, e-commerce, and food innovation. Some of their prominent exits include eBay, Trupanion, and Potbelly Sandwich Works. The firm recently raised $225 million for its eighth fund, continuing its legacy of identifying and supporting early-stage consumer startups. Maveron's team, led by experienced partners like Dan Levitan and Jason Stoffer, brings deep industry knowledge and a commitment to fostering long-term partnerships with entrepreneurs.

Max Ventures, founded in 2013 by Ryan Darnell and Sophie Stenbeck, is a dynamic seed-stage venture capital firm based in New York. Notable for its early investments in companies like Boxed, ZoomCar, Button, and Drone Racing League, Max Ventures focuses on consumer tech and health-tech startups. The fund targets North American markets and emphasizes investing in founders with unique consumer insights and relentless drive. Max Ventures typically makes initial investments ranging from $750K to $1M, often leading the rounds. Their strategy involves a hands-on approach, leveraging their extensive network to support portfolio companies in achieving significant growth. The fund is particularly interested in startups within the fashion/beauty, food and beverage, internet and web services, real estate, and software industries. The team, including key figures like Managing Partner Matthew Weinberg, prides itself on its ability to identify and nurture innovative talent. Startups looking to approach Max Ventures should focus on demonstrating strong consumer insight and a clear execution plan. Recently, the firm has been active with investments like UnityAI in healthcare technology, showcasing their ongoing commitment to pioneering advancements in tech.

Mayfield is a renowned venture capital firm founded in 1969, with a focus on early-stage investments. The firm is based in Menlo Park, California, and has a strong presence in the U.S. and India. Mayfield has made significant contributions to the tech industry, backing over 852 companies, including notable names like Lyft, Couchbase, and Poshmark. Mayfield’s portfolio showcases a diverse range of sectors, emphasizing artificial intelligence, enterprise software, consumer tech, semiconductors, and human and planetary health. Some of their standout investments include Unstoppable Domains, Amagi, and BigPanda, which have grown into unicorns under their guidance. The firm has also successfully shepherded companies to IPO, such as Lyft and Couchbase, and facilitated numerous high-profile acquisitions. The firm operates with a "people-first" investment philosophy, aiming to partner with visionary entrepreneurs from inception through growth stages. They typically invest in Seed, Series A, and Series B rounds, providing not only capital but also strategic support and mentorship. Mayfield's investment team includes seasoned partners like Navin Chaddha and Ursheet Parikh, who bring extensive industry experience and a track record of successful exits. Mayfield's investment strategy involves close collaboration with founders, focusing on building enduring companies that can achieve market leadership. Founders looking to connect with Mayfield should highlight their innovative solutions and potential for significant impact, aligning with the firm’s mission to back transformative technologies.

MBX Capital, established in 2015, is a venture capital firm headquartered in Claymont, Delaware. The firm specializes in early-stage investments within the healthcare and life sciences sectors, focusing on pre-seed, seed, and Series A rounds. MBX Capital has a robust portfolio that includes companies like Luna, Concert Health, Koneksa Health, Atlas Labs, and Buoy Health​. Notable recent investments by MBX Capital include Vivodyne, which raised $38 million in November 2023, and Macro Trials, which secured $6 million in June 2023. These investments underline the firm's commitment to advancing biotechnology and clinical trials​ (PitchBook)​. Additionally, MBX Capital led a $10.7 million Series A financing for Contraline, supporting the development of innovative medical technologies​​. The firm's co-founders, Gurdane Bhutani and Zeshan Muhammedi, lead a team that provides hands-on support to portfolio companies, leveraging their expertise and extensive network to drive growth and innovation​​. MBX Capital's strategic approach and active involvement make it a key player in the venture capital landscape for healthcare and life sciences startups.

Medicxi is a premier European venture capital firm specializing in life sciences, with a focus on drug discovery and therapeutic development. Established in 2016 by the former life sciences team of Index Ventures, the firm has raised over €1 billion across various funds. Medicxi’s flagship funds, such as Medicxi III (€400 million), invest in both early and late-stage biopharma companies. Notable investments include Genmab, Micromet (acquired by Amgen), and Minerva Neurosciences. Medicxi's investment strategy is centered around its "asset-centric" approach, where the firm invests in companies with strong clinical proof-of-concept that address clear unmet medical needs. Their investments typically range between €10 million and €25 million, supporting companies through key phases like clinical development and regulatory approval​. The firm partners closely with major pharmaceutical players such as Novartis, Johnson & Johnson, and GlaxoSmithKline, which provides strategic backing for its portfolio companies​. Headquartered in London, Geneva, and Jersey, Medicxi has become a leading name in European biotech, with a strong emphasis on translating scientific innovation into commercially viable drugs. Their portfolio spans across the full healthcare continuum, from early discovery to late-stage clinical assets, giving them a unique position in Europe’s life sciences ecosystem. Through its deep ties to industry leaders and a robust scientific advisory board, Medicxi continues to drive the next generation of breakthrough therapeutics​.

MedImmune Ventures was the wholly-owned corporate venture capital arm of AstraZeneca, founded in 2002 and headquartered in Gaithersburg, Maryland. The fund managed $400 million in an evergreen structure following AstraZeneca's commitment of an additional $100 million in November 2011. Senior Managing Director Ron Laufer led a team of three partners. Since 2009, the fund operated as a true evergreen vehicle, recycling proceeds from liquidated investments into new portfolio companies rather than returning capital to LPs on a fixed timeline. MedImmune Ventures focused on equity investments in private companies developing small and large molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging, and healthcare IT related to pharmaceutical product discovery and commercialization. Therapeutic areas covered infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system conditions, and gastrointestinal disease. The fund leads rounds. Across approximately 65 investments, the portfolio produced 4 IPOs and 11 acquisitions. Notable holdings include G1 Therapeutics (MedImmune led a $12.5 million Series A in October 2013 and the company later completed a $105 million Nasdaq IPO), Melinta Therapeutics, Astria Therapeutics, and Xencor. The fund also co-led a financing round in NeuProtect Pty Ltd, an Australian cardioprotectant company, alongside Starfish Ventures. MedImmune Ventures is now permanently closed and liquidated. During its active years, the fund served a dual mandate: generating financial returns for AstraZeneca while sourcing strategic intelligence about emerging biotech platforms across areas aligned with the parent company's therapeutic priorities. The evergreen structure allowed for patient capital deployment matched to the long development timelines of biopharmaceutical companies.

Medison Ventures is the corporate venture capital arm of Medison Pharma, one of the world's largest commercial partners for innovative pharmaceutical companies with operations in Israel, Canada, and Eastern Europe. Founded in 2016 by Meir Jakobsohn and headquartered in Petah Tikva, Israel, the firm focuses on in-licensing, equity investments, and scouting for breakthrough technologies in biotechnology and digital health. Investment activity is concentrated at the Series B stage in life sciences companies. The portfolio comprises approximately 10 investments across biotech, pharma, and digital health. Notable holdings include Alpha Tau Medical, an alpha particle cancer therapy company that completed a NASDAQ IPO in March 2021, along with Keros Therapeutics, Eloxx Pharmaceuticals, Apeiron Biologics, Allogene Therapeutics, Orchard Therapeutics, and ArQule. In 2019, Medison Ventures partnered with Pontifax to launch a $150 million venture debt fund providing clinical-stage life science companies with non-dilutive capital. Portfolio companies benefit from direct access to Medison Pharma's global network of pharmaceutical partners including Biogen, Vertex, Shire, BioMarin, IPSEN, Servier, PTC Therapeutics, and Daiichi-Sankyo. The fund's primary value proposition is commercial access: portfolio companies gain introductions to established pharmaceutical distributors and commercial partners through Medison Pharma's existing relationships, potentially accelerating the path from clinical development to market. The fund is currently presumed inactive with no publicly recorded recent investments, reflecting the typical life cycle of a focused corporate VC vehicle tied to its parent's strategic priorities.

Manifold Ventures (MMV) is a venture capital firm focused on supporting early-stage companies in healthcare innovation. Founded by physicians and healthcare entrepreneurs, MMV invests in startups that are developing groundbreaking medical technologies and solutions. The firm is known for its hands-on approach, offering more than just capital; they provide strategic guidance, operational expertise, and access to an extensive network of industry professionals. Their portfolio includes companies like Stellation (patient-provider matching technology), PocketRN (telehealth nursing), and Gradient Health (a healthcare data marketplace). MMV's team, led by Dr. Branden Rosenhan and Dr. Saumitra Thakur, brings deep experience in both clinical practice and business, which they leverage to help their portfolio companies navigate the complexities of the healthcare industry. MMV is headquartered in Salt Lake City and focuses on identifying promising healthcare innovations early in their development cycle, with the goal of helping these startups scale into successful enterprises.

MedVenture Partners, Inc., a Tokyo-based venture capital firm, specializes in early-stage investments within the life sciences sector, with a distinct focus on medical devices and healthcare technologies. Established in 2013 by Hajime Oshita and Dr. Fumiaki Ikeno, the firm has rapidly built a reputation for identifying and nurturing innovative startups poised to disrupt the healthcare landscape. Their portfolio includes standout companies such as Biomedical Solutions, Inc., which exemplifies their commitment to fostering groundbreaking technologies. MedVenture’s investment strategy is characterized by a hands-on approach, often leading funding rounds and providing substantial guidance to portfolio companies. They prioritize startups that demonstrate strong potential for global impact, particularly those addressing critical medical needs. Their geographic focus remains largely on Japan, but they have shown interest in companies that can expand internationally. With over 22 billion Yen in assets under management, MedVenture manages multiple funds, the most recent of which raised 99 billion Yen. The firm’s approach to investment is strategic and collaborative, leveraging deep medical expertise alongside innovative technology. Startups seeking investment should be prepared to present compelling, well-researched pitches that highlight their innovation and market potential. Led by a team of seasoned professionals, including Oshita, who has over two decades of experience in the medical device industry, MedVenture Partners is committed to driving successful exits and significant market advances. Their active involvement in the growth and development of their portfolio companies underscores their role as a key player in Japan’s venture capital landscape.

Menlo Ventures, a Silicon Valley-based venture capital firm, has a robust history of investing in transformative technology companies across consumer, enterprise, and healthcare sectors. Notable investments include Uber, Roku, Warby Parker, Poshmark, and Chime. The firm focuses on early-stage investments but supports companies through their entire growth journey. Menlo Ventures recently closed a $1.35 billion fund aimed at backing the next generation of AI startups, reflecting its commitment to cutting-edge technologies. The firm also emphasizes deep involvement with portfolio companies, offering strategic guidance and support through every stage of development.

Meridian Street Capital is a venture capital firm established in 2016, based in New York City. The firm specializes in early-stage investments at the intersection of healthcare and technology. Their approach is to support founders from the earliest stages, often from day one, to help turn innovative ideas into category-defining companies. Meridian Street Capital has a strong portfolio that includes companies like 1upHealth, ClosedLoop.ai, and Jona Health, among others. They focus on investing in businesses that leverage technology to improve healthcare services, access, and efficiency. Typically, their investments range from $100K to $5M, with a sweet spot around $1.5M. The firm has a hands-on approach, providing strategic guidance and leveraging their industry connections to support the growth of their portfolio companies. The team at Meridian Street Capital includes key figures such as George Ribaroff and T. Scott Law Jr., who bring extensive experience in venture capital and healthcare technology. They have a focused strategy, partnering with a concentrated group of startups to ensure dedicated support and resources. Meridian Street Capital has made a total of 47 investments and has seen several successful exits, including Valify and Hint Health. Their investment strategy emphasizes backing exceptional teams with innovative solutions that have the potential to transform healthcare.

Metaplanet Holdings, founded in 2011 by Jaan Tallinn, co-founder of Skype, is a venture capital firm based in Tallinn, Estonia. The firm focuses on early-stage investments in deep technology startups that promise long-term societal and civilizational impacts. Metaplanet emphasizes funding science-heavy projects and non-commercial research aimed at reducing existential risks, particularly from AI and other advanced technologies. Metaplanet has a diversified portfolio of over 150 startups, with notable investments including BillionToOne, a provider of cell-free cancer liquid biopsy tests, and Anthropic, an AI-based conversational chatbot service. The firm has made more than 50 successful exits, including companies like Ampler Bikes and Apprente. Recent investments include $7 million in the blockchain company Fhenix and $13 million in Neurable, a brain-computer interface technology company. The firm's investment strategy focuses on sectors such as AI, neuroscience, blockchain, and encryption, supporting innovations that have the potential to disrupt industries or create entirely new ones. Metaplanet's team, led by Managing Partner Rauno Miljand and Partner Alexey Morgunov, operates with a lean structure, enabling them to make impactful and strategic investments.

Metavallon VC, founded in 2018 and based in Athens, Greece, focuses on early-stage investments in technology startups, particularly those connected to Greece. They typically invest in seed and pre-seed stages, with initial funding tickets ranging from €500K to €1.5M. The firm emphasizes supporting startups in sectors like transportation and mobility, energy and cleantech, space and aviation, machine learning and AI, and more. Notable investments by Metavallon VC include Ferryhopper, a leading ferry booking platform, and Wikifarmer, which aims to democratize agricultural commerce. The firm has also successfully exited from companies such as Seervision, which specializes in AI-driven camera automation software, and Think Silicon, a provider of graphics technology solutions. Metavallon VC offers extensive support to their portfolio companies, including business development, B2B sales, recruiting, and exit planning. Their approach combines financial backing with hands-on guidance to help startups scale and achieve significant market impact. The leadership team includes George Karantonis, Myrto Papathanou, and Yorgos Mousmoulas, who bring extensive experience in venture capital and technology investments.

Metrodora Ventures is a New York-based venture capital firm founded in 2020 by Chelsea Clinton. The firm focuses on early-stage investments in the health and learning sectors, with a mission to support companies that improve access to care, education, and vital information. Metrodora Ventures is driven by a values-conscious approach, investing in purpose-driven startups that aim to make a significant impact on society. The firm’s portfolio includes innovative companies like Teal Health, which is developing telehealth platforms focused on women’s health, and Blooming Health, which creates technology to help older adults maintain connections with their communities. Another notable investment is Swing Therapeutics, which develops digital therapies for chronic illness management. Metrodora Ventures operates with the goal of nurturing its portfolio companies by providing capital, market insights, and industry relationships. The firm raised its debut fund of $20.8 million and is currently in the process of raising a second fund to continue its mission of fostering impactful startups.

Noshaq is an investment fund based in Liège, Belgium, that offers a range of financing solutions aimed at fostering the creation and growth of companies, particularly SMEs. Established in 1985 under the name Meusinvest, the organization has grown significantly and rebranded to Noshaq in 2019 to better reflect its innovative and dynamic approach to investment. Noshaq manages a portfolio of 477 companies and has supported over 1,020 companies since its inception. The fund's primary focus areas include biotechnology, industry 4.0, digital technology, quality food, real estate, energy, sustainable development, and cultural industries. They provide funding through various vehicles, including equity investments, loans, and leasing, tailored to the specific needs of each stage of a company's development. Notable initiatives under Noshaq include Noshaq Spin-Offs, which supports the creation of spin-offs in collaboration with the University of Liège, and LeanSquare, which focuses on innovative projects in cultural and creative industries, enterprise software, and life sciences. Additionally, Noshaq is actively involved in regional development projects, such as La Grand Poste, a creative hub in the heart of Liège.

MHS Capital, founded in 2006 and based in San Francisco, California, focuses on early-stage investments in technology-driven companies. They have a diverse portfolio, investing across sectors such as software, e-commerce, mobile, and healthcare. Notable investments include companies like Zenput, a business productivity software, and Grove Collaborative, an eco-friendly consumer goods company. MHS Capital has made a total of 102 investments, with 48 successful exits, including companies like Udemy and Thumbtack. The firm emphasizes close collaboration with visionary founders to build the next generation of category-defining companies.

Micron Ventures, the venture capital arm of Micron Technology, focuses on early-stage investments in deep tech startups, particularly those working on AI, machine learning, and innovative hardware solutions. With two dedicated funds—totaling $300 million—the firm aims to accelerate innovations that can transform compute infrastructure and AI-driven applications. Fund II, launched with $200 million, emphasizes deep tech innovations and earmarks 20% of its capital for startups led by women and underrepresented groups. Micron Ventures has a track record of backing high-potential companies, contributing not only capital but also strategic support to help them scale globally. Some notable investments include Aqua Membranes, a clean-tech company focused on sustainable water solutions, and Iterative Scopes, a company leveraging AI to advance healthcare diagnostics. The firm’s portfolio also spans sectors like autonomous systems and cybersecurity, with key investments in SambaNova and Mythic AI. Micron Ventures integrates its investment strategy with its corporate goals, especially in sustainability and AI. By investing in companies at the intersection of hardware and software innovation, Micron Ventures helps push technological boundaries while also advancing Micron’s business objectives.

Middle East Venture Partners (MEVP) is one of the largest and most established venture capital firms in the Middle East, with a focus on investing in early and growth-stage technology startups across the GCC and Levant regions. Founded in 2010, MEVP manages over $300 million in assets and has invested in more than 60 startups, many of which operate in sectors such as fintech, e-commerce, mobility, SaaS, and healthtech. With offices in Dubai, Beirut, Bahrain, and Riyadh, MEVP targets innovative companies that have the potential to scale regionally and globally. Their portfolio includes successful companies like Anghami, the first legal music streaming platform in the Arab world to go public, Nana, a leading online grocery delivery service, and Bykea, a Pakistani super app offering transport and delivery services. MEVP offers both financial backing and strategic support to help these businesses grow, focusing on building sustainable, scalable models that align with local market needs. MEVP has also made significant exits, such as its partial exit from Fresha, a beauty and wellness platform, generating impressive returns. With its recent launch of the $150 million Middle East Venture Fund IV, MEVP continues to drive innovation by supporting digital services and tech-based solutions that address local challenges and tap into global trends​.

Middleland Capital, a venture capital firm founded in 2010 and based in Washington, D.C., focuses on innovative foodtech and agtech companies. With over $100 million invested and a portfolio of 25 direct investments, the firm supports high-growth companies that are looking to scale their de-risked technology and proven business models​. The firm's notable investments include AeroFarms, the largest indoor vertical farming company in the US; Soli Organic, a leading grower and marketer of fresh organic culinary herbs; and MycoTechnology, an ingredient company that utilizes proprietary processes to remove flavor defects in food products without chemicals or GMOs​​. Other significant investments include EarthOptics, which provides real-time soil data maps, and Farmwise, which develops systems to streamline farming operations and increase food production efficiency​. Middleland Capital has a strong track record of successful exits, such as Seventh Generation, which was acquired by Unilever, and Benson Hill, which went public on the NYSE. The firm continues to catalyze global change in food and health through its targeted investments in innovative technologies and sustainable solutions.

MIG AG, based in Munich, Germany, is a prominent venture capital firm investing primarily in deep tech and life sciences. Their notable portfolio includes BioNTech, renowned for its COVID-19 vaccine, and companies like German Bionic, developing exoskeletons, and iOmx Therapeutics, focusing on novel cancer treatments. With over €1.2 billion in committed capital, MIG AG targets early to mid-stage startups that drive technological advancements and societal benefits. Their strategy is to invest in companies with groundbreaking innovations in biopharmaceuticals, medical technology, digital health, advanced computing, and environmental tech. MIG AG is known for its rigorous due diligence and active involvement in portfolio companies, providing strategic support and leveraging an extensive network to foster growth. Key team members include co-founders Jürgen Kosch and Michael Motschmann, both based in Munich, who bring decades of experience in venture capital and entrepreneurship. Startups can approach MIG AG through direct contact or their extensive industry network, emphasizing innovative solutions with strong growth potential. For entrepreneurs seeking investment, MIG AG values clear, impactful pitches that demonstrate significant technological breakthroughs and market readiness.

Milltrust International Group is a specialist investment firm co-headquartered in London and Singapore, known for its focus on sustainable investment strategies. The firm manages assets across public and private markets, with a particular emphasis on addressing global challenges such as food security, climate change, and emerging economies. Their investment philosophy, termed "Sustainable Prosperity," integrates wealth creation with ethical, planet-friendly goals. Milltrust operates through several branches, including Milltrust Ventures, which focuses on venture capital investments in sectors like healthcare, technology, and sustainable agriculture. The firm also manages East West Private Wealth, a multi-family office dedicated to wealth management services that align with eco-conscious and transparent investment strategies. This diverse approach allows Milltrust to support both institutional investors and high-net-worth families globally. In recent years, Milltrust has invested in impactful projects such as sustainable agricultural land in Australia and New Zealand, and high-growth technology companies that promote environmental sustainability.